The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, Augu...
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine....
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis....
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minu...
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?...
The modern pet industry is a testament to the amounts that pet owners and animal lovers are willing to spend on their furry companions. In 2023, U.S. consumers alone spent $147 billion in the pet indu...
IDEXX Laboratories' (IDXX Quick QuoteIDXX - Free Report) business has been suffering due to complex macroeconomic conditions and unfavorable currency movement. The stock carries a Zacks Rank #4 (Sell)...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financia...